Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

Pharmanovia Acquires Global CNS Portfolio from Sanofi

September 18, 2023

Pharmaceuticals

Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.

Juvisé Pharmaceuticals Acquires Ponvory (ex-US/Canada) from Actelion; Bpifrance and Pemberton Invest in Juvisé

March 26, 2024

Pharmaceuticals

Juvisé Pharmaceuticals has acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson company. To fund the transaction, French sovereign fund Bpifrance and private credit manager Pemberton Asset Management took minority stakes in Juvisé; Juvisé will commercialize and assume manufacturing duties for Ponvory in Europe.

Novaremed AG Acquires Metys Pharmaceuticals AG

September 7, 2021

Pharmaceuticals

Novaremed AG acquired Metys Pharmaceuticals AG in an all-share transaction, integrating Metys' clinical and preclinical non-opioid pain programs (including MP-101 and MP-103) into Novaremed's pipeline. The deal broadens Novaremed's focus from painful diabetic peripheral neuropathy (PDPN) to include chemotherapy-induced peripheral neuropathy (CIPN) and strengthens leadership with the election of Andrew J. Oakley to Novaremed's board.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.